A study of variations in the reported haemophilia A prevalence around the world

Abstract

The objectives of this paper were to study the reported haemophilia A prevalence (per 100 000 males) on a country-by-country basis and address the following: Does the reported prevalence of haemophilia A vary by national economies? We collected prevalence data for 106 countries from the World Federation of Hemophilia (WFH) annual global surveys and the literature. We found that the reported haemophilia A prevalence varied considerably among countries, even among the wealthiest of countries. The prevalence (per 100 000 males) for high income countries was 12.8 +/- 6.0 (mean +/- SD) whereas it was 6.6 +/- 4.8 for the rest of the world. Within a country, there was a strong trend of increasing prevalence over time--the prevalence for Canada ranged from 10.2 in 1989 to 14.2 in 2008 (R = 0.94 and P < 0.001) and for the United Kingdom it ranged from 9.3 in 1974 to 21.6 in 2006 (R = 0.94 and P < 0.001). Prevalence data reported from the WFH compared well with prevalence data from the literature. Patient registries generally provided the highest quality of prevalence data. The lack of accurate country-specific prevalence data has constrained planning efforts for the treatment and care of people with haemophilia A. With improved information, healthcare agencies can assess budgetary needs to develop better diagnostic and treatment facilities for affected patients and families and work to ensure adequate supplies of factor VIII concentrates for treatment. In addition, this information can help manufacturers plan the production of concentrates and prevent future shortages.

Descriptive Epidemiology and Complications of Haemophilia in Assiut, Egypt

“…These results were in concordant with the results of multiple previous studies [4], [7]- [9] where the majority of hemophilic cases in their studies were hemophilia A. Also, in the present study, the majority of diagnosed hemophilia cases 51 (68%) their ages were less than 25 years old and only 24 (32%) were more than 25 years old, these results were in agreement with the results of Stonebraker et al [3] and with KAR et al [8] , where the majority of diagnosed hemophilia cases were younger than 25 years old. Gender distribution revealed that 71(94.7%) were males and 4(5.3%) were females.…”

“…So individuals presenting with history of easy bruising, spontaneous joint bleeding, soft tissue hematomas, hematuria or excessive bleeding after trauma or in the post operative setting should be suspected and evaluated for haemophilia. [3] In Egypt which has a population of approximately (90 millions) and frequent consanguineous marriage , autosomal recessive disorders are more prevalent than other areas of the world. According to World Federation of Haemophilia(WFH) survey, 80% of haemophilia patients in the world don't receive any treatment and usually do not survive till adulthood.…”

Long‐term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial

“…

Haemophilia A (factor VIII deficiency) is the most common type of haemophilia [1], affecting approximately 1 in 5000 males, although its prevalence varies globally [2] This letter presents a preplanned interim analysis of data collected up to September 1, 2012 for the guardian TM 2 extension trial. The primary objective is to assess the safety of turoctocog alfa for prevention and treatment of bleeds.

…”

Genetic-Epidemiological Study of Urban and Rural Pediatric Populations in Kharkov Region through the Example of Zmiiv District

“…Поширеність гемофілії у районі була визначена як 1:6194, на Заході України вона становить 1:8385, у Білорусі -1:7752, у Росії -1:4386 [13], у Європі вона складає від 1:2591 у Ісландії до 1:18182 у Боснії та Герцеговині [42], а середньосві-товий показник оцінюється як 1:10000 [41].…”